
By harnessing the innovative potential for circular RNAs as robust biomarkers for brain disorders, Circular Genomics is reshaping the patient-provider relationship in healthcare, elevating the precision of treatment strategies.
Our assay analyzes blood-based circular RNA biomarkers to predict a patient's response to SSRI antidepressants prior to treatment initiation. This expedites treatment and likelihood of recovery, empowering patients to make well-informed decisions about their health.

Precision Psychiatry
![AdobeStock_288579931 [Converted].png](https://static.wixstatic.com/media/2e07ae_78722bcc24ec4f0696460946d2a93f5d~mv2.png/v1/fill/w_256,h_252,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/AdobeStock_288579931%20%5BConverted%5D.png)
circRNA
Circular RNA
Renowned for their stability and neural tissue enrichment, circular RNAs are easily detectable in the blood, making them ideal biomarkers for enhancing brain disorder diagnosis and monitoring.
​
Circular RNAs offer a unique window into a patient's biological status. These biomarkers cross the blood-brain barrier, originating from the brain where they are highly enriched, and can be accessible through a simple blood test.